Full-Time

Manager/Sr. Manager

Communications

Posted on 8/30/2024

Voyager Therapeutics

Voyager Therapeutics

201-500 employees

Develops genetic medicines for neurological diseases

Biotechnology
Healthcare

Mid

Lexington, MA, USA

Category
Public Health
Biology & Biotech
Requirements
  • Minimum of 3 years of communications experience in the biopharma industry, either in-house at a biopharmaceutical company or at an agency
  • Bachelor's degree required, preferably in science, business, or related field
  • Excellent communication skills, both verbal and written, with the ability to articulate complex concepts clearly and concisely to diverse audiences
  • Ability to thrive in a fast-paced, dynamic environment, with a high level of adaptability, flexibility, and resilience to changing priorities and business needs.
  • Ability to collaborate effectively with cross-functional teams at all levels
  • Strong attention to detail and a commitment to accuracy
  • Ability to work independently and use sound judgement and decision-making skills
  • Candidates will be assessed for the level of the role according to their individual experience and capabilities
Responsibilities
  • Lead all digital and social media efforts; create and/or oversee creation and review of all content.
  • Support corporate communications efforts such as press releases, media outreach, and thought leadership, working with external PR firm.
  • Support investor communications materials such as earnings releases, corporate decks, earnings call materials, etc., working with external IR firm.
  • Own visual brand; lead coordination of cohesive use of logo and visual design elements across all departments and materials.
  • Support evolution of corporate narrative working with Chief Corporate Affairs Officer and brand/design firm.
  • Lead strategy and execution for internal communications, including Town Halls, Leadership Communications, Intranet, Newsletter, TVs, and other events/channels.
  • Own creation of all internal communications content (and/or oversee all content creation with agency partner and internal partners, such as HR team).
  • Support corporate-level patient advocacy, including budget/requests for funding, partnering with clinical/medical teams.

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary AAV (adeno-associated virus) capsid discovery platform, which allows for the delivery of genetic material directly to the brain through intravenous dosing. This method addresses the challenge of crossing the blood-brain barrier, which is crucial for effective treatment of brain-related conditions. Unlike many competitors, Voyager Therapeutics emphasizes collaboration with larger pharmaceutical companies to enhance their research and development efforts, which helps them accelerate the creation of new therapies. The company's goal is to provide meaningful treatments that improve the lives of patients suffering from severe neurological disorders.

Company Stage

IPO

Total Funding

$102.1M

Headquarters

Cambridge, Massachusetts

Founded

2014

Growth & Insights
Headcount

6 month growth

1%

1 year growth

2%

2 year growth

3%
Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Novartis could accelerate pipeline and expand market reach.
  • Electric pulse technology may enhance gene therapy delivery efficiency and reduce costs.
  • FDA approval of gene therapy for sickle cell disease may benefit Voyager's initiatives.

What critics are saying

  • Dependency on Novartis collaboration may affect Voyager's R&D autonomy.
  • Leadership changes may indicate potential instability or strategic shifts.
  • Reliance on milestone payments could create financial uncertainty if timelines are delayed.

What makes Voyager Therapeutics unique

  • Voyager's TRACER™ platform enhances CNS drug delivery by penetrating the blood-brain barrier.
  • The company focuses on gene therapies for CNS diseases like ALS and Parkinson's.
  • Voyager's proprietary AAV capsid discovery platform shows promise in preclinical studies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

INACTIVE